Investigation of Cisplatin-Related Kidney Toxicity

Prospective Analysis Group Inclusion Criteria: * Patients about to receive intravenous cisplatin for the first time as part of cancer chemotherapy. * Aged 18 years and older. * Ability to understand and willingness to sign a written consent document. * Patients may be receiving cisplatin in combination with other chemotherapeutic agents. * Patients may be receiving cisplatin in the context of another clinical trial. Exclusion Criteria: * Prior receipt of cisplatin. * Patients on dialysis or other renal replacement therapy prior to starting cisplatin. * Uncontrolled hypo- or hyperthyroidism (patients on chronic stable doses of thyroid replacement medication are eligible). Retrospective Analysis Group Inclusion Criteria: * Patients that have previously received intravenous cisplatin as part of cancer chemotherapy. * Aged 18 years and older. * Ability to understand and willingness to sign a written consent document. * Patients that received cisplatin in combination with other chemotherapeutic agents are eligible. * Patients that received cisplatin in the context of a clinical trial are eligible. Exclusion Criteria: * Unable or unwilling to submit to a one-time blood draw.